CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 156 enrolled
Drug / intervention
Dronabinol +2 moredrug
Likely dose
Dronabinol 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01020019
NCT01020019Phase 3Completed
CompareCT.gov

A Randomized, Double-Blind, Placebo-Controlled Study of Lofexidine and Dronabinol for the Treatment of Marijuana Dependence

New York State Psychiatric Institute·interventional·Posted Nov 25, 2009·Updated Apr 24, 2019

In Brief

A Phase 3 clinical trial evaluating Dronabinol, Placebo, and 1 other intervention for Cannabis Dependence and Marijuana Dependence. Completed, enrolled 156 participants across 1 site.

Detailed Summary

The purpose of this study is to see if Lofexidine in combination with Marinol is superior to placebo in achieving abstinence, reducing cannabis use and reducing withdrawal in cannabis-dependent patients seeking treatment for their marijuana use.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCannabis Dependence, Marijuana Dependence
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 25, 2009
Enrollment StartJan 1, 2010
Primary CompletionSep 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 16.6 years ago

Interventions

Dronabinoldrug

Dronabinol: 20 mg/TID

Placebodrug

Placebo control

Lofexidinedrug

Lofex: .6 mg/ TID